top of page
Experimental modeling supports a role for MyBP-HL as a novel myofilament component in arrhythmia and dilated cardiomyopathy
Loss of dysferlin or myoferlin results in differential defects in excitation–contraction coupling in mouse skeletal muscle
Barefield DY. Et al. Partial and complete loss of myosin binding protein H-like cause cardiac conduction defects. 6;169:28-40. J Mol Cell Cardiol . 2022
Salamone IM. Et al. Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms. 15;132(6). J Clin Invest . 2022
Demonbreun AR. Et. Al. Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy. 8;13(610). Sci Transl Med . 2021
Barefield DY. Et. al. Loss of dysferlin or myoferlin results in differential defects in excitation-contraction coupling in mouse skeletal muscle. 5;11(1):15865. Sci Rep . 2021
Gacita AM. Et. Al. Altered Enhancer and Promoter Usage Leads to Differential Gene Expression in the Normal and Failed Human Heart. Oct;13(10):e006926. Circ Heart Fail . 2020.
Demonbreun AR. Et. Al. A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. Nov 4;13(2). Dis Model Mech . 2019.
Demonbreun AR. Et. Al. Recombinant annexin A6 promotes membrane repair and protects against muscle injury. Nov 1;129(11):4657-4670. J Clin Invest . 2019.
Aubert G. Et. Al. Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective. Apr 29;4(2):251-268. JACC Basic Transl Sci . 2019
Kuster DWD. Et. Al. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy. Cardiovasc Res.1;115(14):1986-1997. Cardiovasc Res. 2019
Barefield DY. Et. Al. Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury. Apr;129:236-246. J Mol Cell Cardiol . 2019.
Kim EY. Et. Al. Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes. 21;4(6):e122686. JCI Insight . 2019
Barefield DY. Garbinicius JF. Highlights from the American Heart Association's Basic Cardiovascular Science 2018 Scientific Sessions. Nov 20;7(22):e011097. J Am Heart Assoc . 2018
Ramratnam M. Et. Al. Transgenic overexpression of the SUR2A-55 splice variant in mouse heart reduces infract size and promotes protective mitochondrial function. Jul 4;4(7):e00677. Heliyon . 2018
Grimes KM Et. Al. The naked mole-rat exhibits an unusual cardiac myofilament protein profile providing new insights into heart function of this naturally subterranean rodent. 469:1603-1613. Pflugers Arch . 2017
Barefield DY. Et. Al. Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy. Oct 17;136(16):1477-1491. Circulation . 2017.
Quattrocelli M. Et. Al. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. Jun 1;127(6):2418-2432. J Clin Invest . 2017.
Barefield DY. High-Throughput Diagnostic Assay for a Highly Prevalent Cardiomyopathy-Associated MYBPC3 Variant. Nov;7(6):303. J Mol Biomark Diagn . 2016.
Demonbreun AR. Et. Al. An actin-dependent annexin complex mediates plasma membrane repair in muscle. Jun 20;213(6):705-18. J Cell Biol . 2016.
Demonbreun AR. Et. Al. Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption. 186(6):1610-22. Am J Pathol . 2016
Taylor EN. Et. Al. Alterations in Multi‐Scale Cardiac Architecture in Association With Phosphorylation of Myosin Binding Protein‐C. Mar 15;5(3):e002836. J Am Heart Assoc . 2016
Lynch TL. Et. Al. Oxidative Stress in Dilated Cardiomyopathy Caused by MYBPC3 Mutation. Oxid Med Cell Longev . 2015
Gao QQ. Et. Al. Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. Nov 2;125(11):4186-95. J Clin Invest . 2015.
McNally EM. Et. Al. The genetic landscape of cardiomyopathy and its role in heart failure. 3;21(2):174-182. Cell Metab . 2015.
Barefield DY. Et. Al. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. Feb;79:234-43. J Mol Cell Cardiol . 2015.
Hoffmann J. Et. Al. Sham Surgery and Inter-Individual Heterogeneity Are Major Determinants of Monocyte Subset Kinetics in a Mouse Model of Myocardial Infarction. 3;9(6):e98456. PLoS One . 2014.
Wang L. Et. Al. Phosphorylation of cMyBP-C Affects Contractile Mechanisms in a Site-specific Manner. Mar 4;106(5):1112-22. Biophys J . 2014.
Barefield DY. Et. Al. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy. Mar 306(6):H807-15. Am J Physiol Heart Circ Physiol . 2014.
Kuster Diederik WD. Et. Al. A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay. Aug 8;(78):50786. J Vis Exp . 2013.
Verma SK. Et. Al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. Jul 24;126(4):418-29. Circulation . 2012
Govindan S. Et. Al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. Jan;52(1):154-64. J Mol Cell Cardiol . 2012
Sadayappan S. Et. Al. A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. Jul 8;109(2):141-50. Circ Res . 2011.
bottom of page